Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $865.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by Piper Sandler from $854.00 to $865.00 in a research note published on Monday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other reports. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a report on Thursday, October 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Royal Bank Of Canada raised their target price on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a report on Thursday, October 8th. Finally, Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $846.28.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $805.67 on Monday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $82.95 billion, a price-to-earnings ratio of 19.91, a P/E/G ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals has a 12 month low of $572.75 and a 12 month high of $859.34. The firm has a 50 day moving average of $791.56 and a two-hundred day moving average of $722.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $12.81 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 48.87 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insider Activity

In related news, insider Andrew J. Murphy sold 4,147 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the sale, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of REGN. Lmcg Investments LLC boosted its stake in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Lmcg Investments LLC now owns 37,703 shares of the biopharmaceutical company’s stock valued at $28,589,000 after purchasing an additional 866 shares during the period. Cardinal Capital Management grew its holdings in Regeneron Pharmaceuticals by 3.8% in the 3rd quarter. Cardinal Capital Management now owns 8,713 shares of the biopharmaceutical company’s stock valued at $6,607,000 after buying an additional 316 shares during the last quarter. Vest Financial LLC grew its holdings in Regeneron Pharmaceuticals by 59.3% in the 3rd quarter. Vest Financial LLC now owns 77,214 shares of the biopharmaceutical company’s stock valued at $58,549,000 after buying an additional 28,732 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $18,881,000. Finally, Axxcess Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $233,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.